Boehringer Ingelheim· @Boehringer · X·· 2026-01-13AI 评分40
AI 导读
#NEWS：我们正在II期试验中测试一款首创抗IL-11抗体。我们的目标：对抗肺瘢痕形成，恢复特发性肺纤维化患者的肺功能，该病全球影响300万+人。 了解更多 https://go.boehringer.com/1JaaO #PulmonaryFibrosis #ClinicalResearch
正文
#NEWS: We’re testing a first-of-its-kind anti-IL-11 antibody in a Phase II trial. Our goal: Fight lung scarring and restore lung function in idiopathic pulmonary fibrosis, which affects 3M+ people globally.
Learn more https://go.boehringer.com/1JaaO
#PulmonaryFibrosis #ClinicalResearch
来源：Boehringer Ingelheim · x.com